This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Danoprevir

Roche Holding AG

Drug Names(s): ASC08, ITMN-191, ITMN B, R7227, RO5190591, RG7227

Description: Danoprevir is a macrocyclic peptidomimetic small molecule compound that competitively inhibits the HCV NS3/4A protease.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

Array and InterMune
Array and InterMune have collaborated since 2002 to discover novel small molecule inhibitors of the Hepatitis C Virus (HCV) NS3/4 protease. During fiscal 2005, this collaboration was extended and expanded. During fiscal 2006, Array developed and delivered cGMP clinical supplies for ITMN-191. Under the terms of the agreement, InterMune funds drug discovery, preclinical testing, process development and cGMP manufacturing conducted by Array and will make milestone payments to Array based on the selection and progress of clinical drug candidates, as well as royalties on sales of any products derived from the collaboration.

Roche and InterMune
Roche and InterMune announced in October 2006 that the companies entered into an exclusive worldwide collaboration agreement to develop and commercialize products from InterMune's HCV protease inhibitor program. The agreement includes...See full deal structure in Biomedtracker

Partners: Array BioPharma, Inc. Ascletis, Inc.


Danoprevir News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug